Claims for Patent: 10,034,931

Summary for Patent: 10,034,931

Title:	Use of EGFR pathway inhibitors to increase immune responses to antigens
Abstract:	This disclosure relates to using EGFR pathway inhibitors in combination with compositions comprising an antigen to increase, elicit, or improve an antigen or vaccine-induced immune response. In certain embodiments, the EGFR pathway inhibitor is administered under conditions such that memory cells to the antigen are formed in a subject. In certain embodiments, the composition is a vaccine. In certain embodiments, the EGFR pathway inhibitor and vaccine are administered to the skin epidermis or dermis.
Inventor(s):	Pollack Brian P., Compans Richard W., Pulit-Penaloza Joanna A., Skountzou Ioanna
Assignee:	Emory University
Application Number:	US15024102
Patent Claims:

Details for Patent 10,034,931

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Biogen Inc.	TYSABRI	natalizumab	Injection	125104	November 23, 2004	10,034,931	2034-09-23
Glaxosmithkline Biologicals	FLUARIX, FLUARIX QUADRIVALENT	influenza vaccine	Injection	125127	August 31, 2005	10,034,931	2034-09-23
Glaxosmithkline Biologicals	FLUARIX, FLUARIX QUADRIVALENT	influenza vaccine	Injection	125127	December 14, 2012	10,034,931	2034-09-23
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163	October 05, 2006	10,034,931	2034-09-23
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163	November 10, 2009	10,034,931	2034-09-23
Id Biomedical Corporation Of Quebec	FLULAVAL, FLULAVAL QUADRIVALENT	influenza vaccine	Injection	125163	August 15, 2013	10,034,931	2034-09-23

International Patent Family for US Patent 10,034,931

Country	Patent Number	Estimated Expiration
World Intellectual Property Organization (WIPO)	2015042567
United States of America	2016228533